Prica & Partners advises AbbVie on local aspects of Allergan acquisition
At the end of last year, around 70 percent of shareholders of Allergan plc. (producer of pharmaceuticals mainly in aesthetic medicine sector, including botulinum toxin, widely known as botox) voted for the approval of the acquisition of the company by AbbVie Inc., one of the global leaders in pharmaceutical industry. The transaction was closed in May 2020.
Since then, the process of integration and transfer of assets is ongoing and Prica & Partners is proud to be a local advisor to AbbVie and assist in a smooth transfer in this complex, yet challenging transaction, with the global value of around 63 billion US dollars.